Literature DB >> 21521881

Lack of B and T lymphocyte attenuator exacerbates autoimmune disorders and induces Fas-independent liver injury in MRL-lpr/lpr mice.

Yoshihiro Oya1, Norihiko Watanabe, Yoshihisa Kobayashi, Takayoshi Owada, Mie Oki, Kei Ikeda, Akira Suto, Shin-ichiro Kagami, Koichi Hirose, Takashi Kishimoto, Hiroshi Nakajima.   

Abstract

MRL/Mp-Fas (lpr) (MRL-lpr) mice develop a systemic autoimmune disease and are considered to be a good model for systemic lupus erythematosus in humans. We have recently shown that mice lacking B and T lymphocyte attenuator (BTLA), an inhibitory co-receptor expressed mainly on lymphocytes, on a 129SvEv background spontaneously develop lymphocytic infiltration in multiple organs and an autoimmune hepatitis (AIH)-like disease. In this study, we investigated the role of BTLA in the pathogenesis of autoimmune diseases in MRL-lpr mice. We found that BTLA-deficient (BTLA(-/-)) MRL-lpr/lpr mice developed severe lymphocytic infiltration in salivary glands, lungs, pancreas, kidneys and joints as compared with BTLA-sufficient (BTLA(+/+)) MRL-lpr/lpr mice. In addition, although AIH-like disease was not found in BTLA(+/+) MRL-lpr/lpr mice, AIH-like disease was exacerbated in BTLA(-/-) MRL-lpr/lpr mice as compared with that in BTLA(-/-) 129SvEv mice. These results suggest that BTLA plays a protective role in autoimmune diseases in MRL-lpr mice and that AIH-like disease develops in BTLA(-/-) mice even in the absence of Fas-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521881     DOI: 10.1093/intimm/dxr017

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  15 in total

Review 1.  Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

Authors:  Stephanie Grebinoski; Dario Aa Vignali
Journal:  Curr Opin Immunol       Date:  2020-06-30       Impact factor: 7.486

Review 2.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 3.  T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy.

Authors:  Amir Sharabi; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2020-01-16       Impact factor: 20.543

4.  Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells.

Authors:  Matthieu Sawaf; Jean-Daniel Fauny; Renaud Felten; Flora Sagez; Jacques-Eric Gottenberg; Hélène Dumortier; Fanny Monneaux
Journal:  JCI Insight       Date:  2018-07-12

5.  BTLA Expression and Function Are Impaired on SLE B Cells.

Authors:  Annika Wiedemann; Marie Lettau; Sarah Y Weißenberg; Ana-Luisa Stefanski; Eva-Vanessa Schrezenmeier; Hector Rincon-Arevalo; Karin Reiter; Tobias Alexander; Falk Hiepe; Andreia C Lino; Thomas Dörner
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 6.  Coinhibitory molecules in autoimmune diseases.

Authors:  Norihiko Watanabe; Hiroshi Nakajima
Journal:  Clin Dev Immunol       Date:  2012-09-11

Review 7.  BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.

Authors:  Xueping Yu; Yijuan Zheng; Richeng Mao; Zhijun Su; Jiming Zhang
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

8.  BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease.

Authors:  Christoph Oster; Benjamin Wilde; Christof Specker; Ming Sun; Andreas Kribben; Oliver Witzke; Sebastian Dolff
Journal:  Int J Mol Sci       Date:  2019-09-11       Impact factor: 5.923

Review 9.  The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus.

Authors:  Kun-Lin Lu; Ming-Ying Wu; Chi-Hui Wang; Chuang-Wei Wang; Shuen-Iu Hung; Wen-Hung Chung; Chun-Bing Chen
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

Review 10.  Immunotherapies: the blockade of inhibitory signals.

Authors:  Yan-Ling Wu; Jing Liang; Wen Zhang; Yoshimasa Tanaka; Hiroshi Sugiyama
Journal:  Int J Biol Sci       Date:  2012-11-17       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.